English NHS must fund value based pricing system drugs
This article was originally published in Scrip
Executive Summary
England's Department of Health yesterday gave pharmaceutical companies a little more clarity on what the new value-based pricing system might have in store when it confirmed that the National Health Service in England will have to fund drugs that are subject to the new system. The news could mean fewer barriers than anticipated to the uptake of new medicines. Nevertheless the BioIndustry Association (BIA), representing UK biotech firms, warned that the new system could make the UK a less attractive location to launch medicines.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.